Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13390386 | 1.00 | CHRM2 (0.42) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL29017255 | 1.00 | CHRM2 (0.42) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL1440499 | 1.00 | CHRM2 (0.42) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL29017210 | 1.00 | CHRM2 (0.42) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL8220061 | 1.00 | CHRM2 (0.42) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL3302448 | 0.98 | CHRM2 (0.41) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL12699742 | 0.85 | CHRNB2 (0.40) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL28560927 | 0.85 | CHRNB2 (0.40) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL18308390 | 0.85 | CHRNB2 (0.40) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL3976273 | 0.85 | CHRNB2 (0.40) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4192833-B1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2026-01-21 | — | — | EP | disclosed |
| US-12473293-B2 | Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | RICHTER GEDEON NYRT. (HU) | 2025-11-18 | — | — | US | disclosed |
| US-20230286988-A1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2023-09-14 | — | — | US | disclosed |
| EP-4192833-A1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES | Richter Gedeon Nyrt. (HU) | 2023-06-14 | — | — | EP | disclosed |
| CN-116075514-A | Pharmacologically active heterocyclic substituted pyrazolo [1,5-a ] pyrimidine derivatives | 吉瑞工厂 | 2023-05-05 | — | — | CN | disclosed |
| US-20230046457-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN MA INC. | 2023-02-16 | — | — | US | disclosed |
| US-20100093706-A1 | MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PREXA PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093706-A1 | MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PREXA PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2008024371-A2 | MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PREXA PHARMACEUTICALS, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046457-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | CHRM2 4863/4885CHRM4 4830/4885CHRM3 4734/4885 |
| US-20100093706-A1 | MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | SLC6A4, SLC18A2, SLC6A2 | CHRM2 2401/4885CHRM4 1229/4885CHRM3 1784/4885 |
| US-20230286988-A1 | PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES | GABRA5, GABRA1, P2RX5 | CHRM2 381/4885CHRM4 364/4885CHRM3 210/4885 |
| US-12473293-B2 | Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives | GABRA5, GABRA1, P2RX5 | CHRM2 381/4885CHRM4 364/4885CHRM3 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.